NR4A1 and neoplasm: We performed immunohistochemical analysis for DEK expression on a tissue microarray that consisted of 30 invasive breast carcinomas and compared expression levels with numerous clinical and pathological variables including patient age, tumor grade, tumor stage, tumor size, lymph node status, HER2 expression, and hormone receptor status.